High Levels of Serum Uric Acid, Cystain C and Lipids Concentration and their Clinical Significance in Primary Gouty Arthritis Patients

Author(s): Quan-Bo Zhang, Dan Zhu, Zhong Wen, Ting Yi, Qing Li, Yu-Feng Qing*, Jing-Guo Zhou.

Journal Name: Current Rheumatology Reviews

Volume 15 , Issue 2 , 2019

Become EABM
Become Reviewer

Abstract:

Objective: To investigate the changes of serum Uric Acid (sUA), lipids and Cystatin C (CysC) in primary gout patients, and to explore the clinical significance in gout patients.

Methods: sUA, CysC, high-sensitivity C-reactive Protein (hsCRP) and other biochemical parameters were measured in 326 gout patient and 210 healthy control subjects, blood cell counts were also detected. Clinical data were collected from gout patients.

Results: sUA, CysC, hsCRP, Body Mass Index (BMI), White Blood Cell (WBC) counts, neutrophil Granulocyte (GR), Monocyte (Mo), Triglycerides (TG), plasma Total Cholesterol (TC), Very Low Density Lipoprotein (VLDL), apolipoprotein B100 (apoB100), Blood Glucose (GLU), serum Creatinine (sCr) and Urea Nitrogen (BUN) were significantly increased in gout patients compared with HC subjects (P<0.01, respectively), while lymphocyte counts and High Density Lipoprotein- Cholesterol (HDL-C) were significantly decreased in gout patients compared with HC subjects (P<0.01, respectively). Positive correlations were observed between concentration of sUA and age, TG, VLDL, sCr and CysC (P<0.05, respectively). While negative correlations were observed between the concentration of sUA and HDL-C(P<0.01). Besides, Positive correlations were observed between concentration of CysC and WBC, GR, Mo, apoA1, GLU, sCr, BUN, sUA, hsCRP (P<0.05, respectively). While negative correlations were observed between the concentration of CysC and TC, LDL-C(P<0.01, respectively).

Conclusions: Blood lipid profile changes in gout patients. Gout patients who suffer from lipid metabolism disorder and vascular diseases might be associated with hyperuricemia, which leads to endothelial cell damage and vascular smooth muscle cell proliferation. CysC might be a marker for renal function damage and inflammation. Hyperuricemia is the risk factor of renal disorder in gout patients.

Keywords: Gout, primary, uric acid, cystatin C, lipids, arthritis patients.

[1]
Richette P, Bardin T. Gout Lancet 2010; 375(9711): 318-28.
[2]
Hong Q, Qi K, Feng Z, et al. Hyperuricemia induces endothelial dysfunction via mitochondrial Na+/Ca2+ exchanger-mediated mitochondrial calcium overload. Cell Calcium 2012; 51(5): 402-10.
[3]
Abeles AM. Hyperuricemia, gout, and cardiovascular disease: An update. Curr Rheumatol Rep 2015; 17(3): 13.
[4]
Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med 2008; 75(Suppl. 5): S13-6.
[5]
Borghi C, Rosei EA, Bardin T, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens 2015; 33(9): 1729-41.
[6]
Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007; 116(8): 894-900.
[7]
Katsiki N, Karagiannis A, Athyros VG, Mikhailidis DP. Hyperuricaemia: More than just a cause of gout? J Cardiovasc Med (Hagerstown) 2013; 14(6): 397-402.
[8]
Tsai HT, Wang PH, Tee YT, Lin LY, Hsieh YS, Yang SF. Imbalanced serum concentration between cathepsin B and cystatin C in patients with pelvic inflammatory disease. Fertil Steril 2009; 91(2): 549-55.
[9]
Neogi T, Jansen TLTA, Dalbeth N. Gout classification criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum 2015; 69: 1580-8.
[10]
Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004; 44(4): 642-50.
[11]
Chonchol M, Shlipak MG, Katz R, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007; 50(2): 239-47.
[12]
Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 2008; 19(12): 2407-13.
[13]
Krishnan E. Inflammation, oxidative stress and lipids: The risk triad for atherosclerosis in gout. Rheumatology (Oxford) 2010; 49(7): 1229-38.
[14]
Liu D, Ji L, Zhang D, et al. Nonenzymatic glycation of high-density lipoprotein impairs its anti-inflammatory effects in innate immunity. Diab/Metabol Res Rev 2012; 28: 168-95.
[15]
Jin M, Yang F, Yang I, et al. Uric acid, hyperuricemia and vascular diseases. Front Biosci 2012; 17: 656-69.
[16]
Abuja PM. Ascorbate prevents prooxidant effects of urate in oxidation of human low density lipoprotein. FEBS Lett 1999; 446(2-3): 305-8.
[17]
Bagnati M, Perugini C, Cau C, Bordone R, Albano E, Bellomo G. When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: A study using uric acid. Biochem J 1999; 340(Pt 1): 143-52.
[18]
Patterson RA, Horsley ET, Leake DS. Prooxidant and antioxidant properties of human serum ultrafiltrates toward LDL: important role of uric acid. J Lipid Res 2003; 44(3): 512-21.
[19]
Krishnan E. Inflammation, oxidative stress and lipids: The risk triad for atherosclerosis in gout. Rheumatology (Oxford) 2010; 49(7): 1229-38.
[20]
Suzuki T. Nitrosation of uric acid induced by nitric oxide under aerobic conditions. Nitric Oxide 2007; 16(2): 266-73.
[21]
Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008; 26(2): 269-75.
[22]
Spiga R, Marini MA, Mancuso E, et al. Uric acid is associated with inflammatory biomarkers and induces inflammation via activating the NF-κB signaling pathway in HepG2 cells arterioscler. Arterioscler Thromb Vasc Biol 2017; 37(6): 1241-9.
[23]
Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: Implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16(12): 3553-62.
[24]
Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002; 106(2): 221-6.
[25]
Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38(5): 1101-6.
[26]
Stack A, Manolis AJ, Ritz E. Detrimental role of hyperuricemia on the cardio-reno-vascular system. Curr Med Res Opin 2015; 31(Suppl. 2): 21-6.
[27]
Kato M, Hisatome I, Tomikura Y, et al. Status of endothelial dependent vasodilation in patients with hyperuricemia. Am J Cardiol 2005; 96(11): 1576-8.


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 15
ISSUE: 2
Year: 2019
Page: [141 - 145]
Pages: 5
DOI: 10.2174/1573397114666180705095625
Price: $58

Article Metrics

PDF: 56
HTML: 2